section name header

Pronunciation

thye-oh-GWON-een

Classifications

Therapeutic Classification: antineoplastics

Pharmacologic Classification: antimetabolites

Indications

High Alert

Action

Therapeutic Effects:

Pharmacokinetics

Absorption: Variable and incomplete (average, 30%) following oral administration.

Distribution: Probably does not enter the CSF. Crosses the placenta.

Metabolism/Excretion: Highly metabolized by the liver; undergoes methylation via thiopurine methyltransferase (TPMT).

Half-life: 11 hr.

Time/Action Profile

(effect on blood counts)

ROUTEONSETPEAKDURATION
PO7–10 days14 days21 days

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Derm: dermatitis, rash.

EENT: loss of vibratory sense.

GI: anorexia, diarrhea, hepatic veno-occlusive disease, hepatotoxicity, jaundice, nausea, stomatitis, vomiting.

GU: gonadal suppression.

Hemat: anemia, leukopenia, pancytopenia, thrombocytopenia.

Metab: hyperuricemia.

Neuro: unsteady gait.

Interactions

Drug-Drug:

Route/Dosage

see Calculator

Many other protocols are used

Availability

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Tabloid

Canadian Brand Names

Lanvis